Patients with ERCCI-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4225-4231

  Kim, Min Kyoung ^a,b   Cho, Kyung Ja ^a   Kwon, Gui Young ^a   Park, Seung Il ^a   Kim, Yong Hee ^a   Kim, Jong Hoon ^a   Song, Ho Young ^a   Shin, Ji Hoon ^a   Jung, Hwoon Yong ^a   Lee, Gin Hyug ^a   Choi, Kee Don ^a   Kim, Sung Bae ^a  

^a Asan Medical Center   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; ENDOSCOPIC BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; MALE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOPSY; BIOSYNTHESIS; CLINICAL TRIAL; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; TIME; TREATMENT OUTCOME;

AGED; BIOPSY; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 48249135539     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4848     Document Type: Article

References (24)

1. Shin HR, Jung KW, Won YJ, Park JG. 2002 Annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103-14.
2. Urba SG, Orringer MB, Turrisi A, lannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
3. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
4. Tepper JE, Krasna M, Niedzwiecki D, et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781 [abstract 4012]. J Clin Oncol 2006;24:18S.
5. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-7.
6. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004;15:947-54.
7. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
8. Kwon HC, Ron M, Oh S, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007;18:504-9.
9. Joshi MB, ShirotaY, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11: 2215-21.
10. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 2008;44:54-60.
11. Lee JL, Kim SB, Jung HY, et al. Efficacy of neoadjuvant chemoradiotherapy in resectable esophageal squamous cell carcinoma-a single institutional study. Acta Oncol 2003;42:207-17.
12. Kim SB, Park SI, Kim JH, et al. A phase II trial of preoperative one cycle of induction chemotherapy [capecitabine(CAP), CDDP] followed by concurrent chemoradiation (CRT) in patients with resectable esophageal cancer [abstract 4063]. J Clin Oncol 2005;23:16S.
13. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006; 355:983-91.
14. Richmond RC. Toxic variability and radiation sensitization by dichlorodiammineplatinum(11) complexes in Salmonella typhimurium cells. Radiat Res 1984;99: 596-608.
15. Yang LX, Douple EB, Wang HJ. Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys 1995;33:641-6.
16. Lindahl T, Wood RD. Quality control by DNA repair. Science1999;286:1897- 905.
17. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatinbased chemotherapy. Ann Oncol 2007;18:522-8.
18. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127:978-83.
19. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8.
20. Wei Q, Frazier ML, Levin B. DNA repair: a doubleedged sword. J Natl Cancer Inst 2000;92:440-1.
21. Spitz MR, Wei Q, Li G, Wu X. Genetic susceptibility to tobacco carcinogenesis. Cancer Invest 1999;17: 645-59.
22. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair crosscomplementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25: 2747-54.
23. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol 2002;20:1932-41.
24. Luthra R, WuTT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259-67.